Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacokinetic Study of an Optimized Dose Ratio of Dolutegravir/Emtricitabine/Tenofovir Alafenamide Fumarate: Expediting a UNIVERSAL First Line Regimen for All Children Living With HIV in Africa

NCT05993767 is registered in ClinicalTrials.gov with PENTA Foundation as lead sponsor.

NCT NCT05993767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05993767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacokinetic Study of an Optimized Dose Ratio of Dolutegravir/Emtricitabine/Tenofovir Alafenamide Fumarate: Expediting a UNIVERSAL First Line Regimen for All Children Living With HIV in Africa
Lead sponsor
PENTA Foundation
Phase
Phase 2
Overall status
Completed
Start date
December 11, 2024
Completion date
January 20, 2026
Enrollment
53 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infection